Biogen is continuing to actively recruit Alzheimer’s patients for its Phase 4 ICARE AD-US trial, which is evaluating the…
Articles by Marta Figueiredo, PhD
Eisai has partnered with Geisinger to assess whether a machine-learning model can accurately identify people with cognitive impairment…
Atuzaginstat (COR388), Cortexyme’s investigational oral therapy, effectively suppressed the activity of its target — toxic enzymes called gingipains —…
The blood levels of two biomarkers of Alzheimer’s disease are significantly associated with changes in brain beta-amyloid deposits and…
Six months of daily supplements of omega-3 increased the levels of two biomarkers of inflammation and nerve damage in the…
A Phase 3 trial testing NE3107, BioVie’s experimental anti-inflammatory insulin-sensitizing therapy, in adults with mild to moderate Alzheimer’s…
Most amyloid-related imaging abnormalities (ARIA) occurring in Alzheimer’s patients receiving Aduhelm (aducanumab) are temporary, moderate in severity, and asymptomatic…
Limiting air pollution may slow cognitive decline and lower the risk of dementia for older women, according to three analyses…
Researchers have identified new mutations in six genes that may increase the risk of developing Alzheimer’s disease. Their study…
Activation of the sigma-1 receptor or SIGMAR1 — whose production is typically increased with age, but reduced in people with…